Supplementary Table S1 Adverse events recorded during the study

Subject nr.	Tariquidar dose (mg/kg)	Description of adverse event	Severity	Outcome	Relationship to study drug
01	3	dysgeusia	mild	recovered	probable
02	3	vertigo	mild	recovered	probable
03	3	pain in right shoulder	mild	recovered	unlikely
06	4	abdominal discomfort	mild	recovered	unlikely
06	4	dysgeusia	mild	recovered	probable
08	4	hematoma due to arterial cannulation	mild	recovered	not related
09	4	event of intermittent ectope atrial rhythm (preexisting condition)	mild	recovered	not related
11	6	multiple hematoma (back and upper arms, due to sports injury)	mild	recovered	not related
12	6	dysgeusia	mild	recovered	probable
12	6	headache	mild	recovered	possible
13	6	dysgeusia	mild	recovered	probable
13	6	hematoma due to cannulation left cubita and wrist	mild	recovered	not related
14	6	dysgeusia	mild	recovered	probable
14	6	hematoma due to cannulation left wrist	mild	recovered	not related
15	6	hematoma due to cannulation left wrist	mild	recovered	not related
16	8	vertigo	mild	recovered	possible
16	8	phlebitis left cubita	mild	recovered	not related
17	8	dysgeusia	mild	recovered	probable
20	7.2[a]	vertigo	mild	recovered	possible
20	7.2[a]	hypotension	moderate	recovered	possible
20	7.2[a]	bradycardia	mild	recovered	possible

[a] Due to moderate hypotension of the subject the tariquidar infusion was discontinued prematurely, resulting in an effective tariquidar dose of 7.2 mg/kg.

Supplementary Table S2 Tariquidar doses, infusion durations and tariquidar plasma concentrations at start and end of PET scan measured with liquid chromatography tandem mass spectrometry in subjects undergoing PET examination

Subject nr.	Tariquidar dose (mg/kg)	Tariquidar dose (mg)	Duration of infusion (min)	Tariquidar plasma concentration at start of PET (ng/mL)	Tariquidar plasma con-centration at end of PET (ng/mL)
pilot 1[a]	2	168	30	407	535
pilot 2	2	140	30	793	965
pilot 3	2	150	30	416	450
pilot 4	2	146	30	324	281
pilot 5	2	137	30	451	451
03	3	192	30	n.a.[b]	n.a.[b]
04	3	177	30	n.a.[b]	n.a.[b]
05	3	216	30	691	581
08	4	328	87	824	525
09	4	348	93	903	845
10	4	316	84	735	604
13	6	630	168	831	923
14	6	552	147	1,087	976
15	6	552	147	757	902
18	8	512	137	732	671
19	8	608	162	1,312	1,241
20	7.2[c]	603	161	885	762

n.a., not available

[a] Subjects designated as “pilot” are taken from previous study (17)

[b] Samples lost due to technical failure.

[c] Due to moderate hypotension of the subject the tariquidar infusion was discontinued prematurely, resulting in an effective tariquidar dose of 7.2 mg/kg.